Specifically, the view supported by our groups and others [9,14,45,107,108] that the autocrine IGF-II/IRA ligand–receptor complex in cancer bears the required biological relevance and contextual pathological value would justify such a therapeutic strategy. Here, IGF2 is linked to cancer.